PharmaCyte Biotech is a preclinical-stage biopharmaceutical company developing Cell-in-a-Box®, a proprietary encapsulation technology that protects genetically modified human cells from immune rejection while enabling targeted therapeutic delivery. The company's lead program focuses on treating locally advanced pancreatic cancer and other cancer and metabolic diseases by delivering therapeutic agents directly to tumors, with the goal of overcoming limitations of systemic therapies through localized treatment. PharmaCyte is pre-revenue and funds operations through equity and debt financing and strategic portfolio investments in complementary biotech companies; the company is currently working to complete preclinical studies and satisfy FDA requirements to advance its technology toward clinical trials.